AYTU BioPharma
AYTU
30 hedge funds and large institutions have $2.5M invested in AYTU BioPharma in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 7 closing their positions.
0.37% less ownership
Funds ownership: 0.84% → 0.47% (-0.37%)
6% less funds holding
Funds holding: 32 → 30 (-2)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
58% less capital invested
Capital invested by funds: $6.03M → $2.5M (-$3.53M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$236K |
| 2 |
Renaissance Technologies
New York
|
+$186K |
| 3 |
Two Sigma Investments
New York
|
+$26.2K |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$26.1K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$20.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2.57M |
| 2 |
Millennium Management
New York
|
-$58.3K |
| 3 |
Goldman Sachs
New York
|
-$54K |
| 4 |
BlackRock
New York
|
-$40.5K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$36.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
|
AC
27
Armistice Capital
New York
| – | -$2.57M | -118,997 | Closed |
|
|
28
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$36.7K | -2,869 | Closed |
|
|
29
Goldman Sachs
New York
| – | -$54K | -2,507 | Closed |
|
|
SSA
30
Schonfeld Strategic Advisors
New York
| – | -$18K | -845 | Closed |
|
|
PFS
31
Prospera Financial Services
Dallas,
Texas
| – | -$1K | -25 | Closed |
|
AYTU Hedge Fund Activity: Q2 2022 in Review
30 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q2 2022, worth a combined $2.5M — down 58% from $6.03M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of AYTU and 6 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $236K. The largest seller was Armistice Capital, exiting entirely with an estimated $2.57M sold.
- 30 institutional investors held AYTU BioPharma (AYTU) as of Q2 2022, down from 32 in Q1 2022.
- Funds reported $2.5M of AYTU BioPharma stock for Q2 2022, down 58% quarter-over-quarter.
- 6 funds opened new AYTU BioPharma positions in Q2 2022 and 7 closed out, a net change of -1 holder.
- The largest AYTU BioPharma buyer in Q2 2022 was Vanguard Group, an estimated $236K added.
- The largest AYTU BioPharma seller in Q2 2022 was Armistice Capital, an estimated $2.57M sold.
Based on aggregated 13F filings for Q2 2022.